Combination of STING agonist with anti-vascular RGD-(KLAKLAK)2 peptide as a novel anti-tumor therapyJustyna Czapla(National Institute of Oncology), Ryszard Smolarczyk(National Institute of Oncology)Cancer Immunology ImmunotherapyJune 4, 202410.1007/s00262-024-03732-3Cited by 14SaveCiteExport RISWatch citationsRelated PapersDifferential Response to Local Stimulator of Interferon Genes Agonist Administration in Tumors with Various Stimulator of Interferon Genes Statuses|Cancers|2025|2